Is the Mayne Pharma Group Ltd share price heading lower?

On Tuesday the Mayne Pharma Group Ltd (ASX: MYX) share price finished the day just 1.5 cents higher than its multi-year low of 60 cents.

This means the pharmaceutical company’s shares have now lost almost two-thirds of their value since this time last year.

Are they in the bargain bin now?

That’s the million dollar question. If pricing pressures ease in the U.S. generic drugs market then there’s every chance that Mayne Pharma will prove to be an absolute steal at the current share price.

But as I explained at the start of the month, the generic drugs market is showing no signs of a recovery in prices just yet.

Global generic drugs giant Teva Pharmaceutical saw its shares shed 20% of their value on November 2 after its Generic Drugs segment posted a 37% decline in quarterly profit to US$619 million.

Furthermore, Teva revised its full-year guidance lower and failed to provide any upbeat commentary on the industry. In light of this, I feel it could be some time before generic drug prices recover, which could mean the Mayne Pharma share price decline hasn’t ended yet.

What now?

Instead of risking your hard-earned money in Mayne Pharma I would suggest you consider fellow healthcare share CSL Limited (ASX: CSL). I think it is capable of growing its bottom line at a solid rate for the foreseeable future thanks to its immunoglobulins, specialty products, and vaccines businesses.

As well as CSL, these tech shares could be great investment options in 2018.

Analyst reveals 3 revolutionary tech companies to watch on the ASX

Entire new industries and technologies unheard of 15 years ago are now regular parts of our lives.

It's difficult to keep up with new developments - but if you think things are changing fast now, you haven't seen anything yet. We're in the midst of a technology revolution full of opportunities to make huge amounts of money.

We've found 3 Aussie companies at the forefront of this revolution. For everything you need to know, go here!

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.